As of Nov 20, 2026, 0 of 1 active firms rate BRTX a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
BRTX EPS & revenue forecast
EPS · NEXT QUARTER
$-2.60
Range $-2.60 – $-2.60 · 1 analysts · -61% YoY
Next period, 1 analysts expect BioRestorative Therapies Inc to earn $-2.60 a share (range $-2.60 – $-2.60), versus $-6.60 a year earlier. Full-year consensus is $-13.20, growing to $-10.40 the year after.
REVENUE · NEXT QUARTER
—
Range — – — · 1 analysts
Revenue is expected to reach — (range — – —). Full-year consensus is $310.0K, rising to $1.5M next year.
Top analysts covering BioRestorative Therapies Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BRTX.
#1
Jonathan Aschoff
Roth MKM · Rank #588
Buy
$15.00+1045.0% to target
Overall win rate
28%
+ Follow
#2
Michael Okunewitch
Maxim Group
Neutral
No targeton BRTX
Coverage
—
+ Follow
BRTX stock forecast FAQ
Is BRTX stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 20, 2026, 0 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover BRTX?+
1 active firms have a recognized rating on BioRestorative Therapies Inc as of Nov 20, 2026.
Who is the most accurate analyst covering BRTX?+
Among analysts who currently cover BRTX, Jonathan Aschoff of Roth MKM has the strongest overall Quantellect track record (Rank #588). Their current call is Buy with a $15.00 target.
What is BioRestorative Therapies Inc's projected EPS for next quarter?+
The consensus estimate is $-2.60 per share (range $-2.60 – $-2.60) across 1 analysts. Full-year EPS is projected at $-13.20, rising to $-10.40 the following year.
How much revenue is BioRestorative Therapies Inc expected to report next quarter?+
Consensus revenue is — (range — – —). Full-year revenue is projected at $310.0K, growing to $1.5M next year.
Have analysts been upgrading or downgrading BRTX lately?+
As of Nov 20, 2026, 0 of 1 active firms rate BRTX a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BRTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.